Immix Biopharma, Inc. - Common Stock (IMMX)

LOS ANGELES,CA, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL amyloidosis and select immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted RMAT designation to sterically-optimized CAR-T NXC-201 for the treatment of relapsed/refractory AL amyloidosis. As of June 2024 public information, FDA approved less than half of RMAT applications submitted to the agency during the last eight years. FDA RMAT designation requires that a drug is an advanced regenerative medicine, targets a serious condition, with the potential to treat, modify, reverse, or cure, and preliminary clinical evidence has indicated that the drug has the potential to address these unmet medical needs.

LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases, today announced successful completion of the six-patient Phase 1b safety run-in segment in the U.S. NEXICART-2 study of NXC-201, an investigational CAR-T therapy, in patients relapsed/refractory (R/R) AL Amyloidosis. Achievement of this milestone is expected to accelerate enrollment across U.S. study sites beginning in January 2025.

- Company management will provide an update on positive new developments regarding CAR-T NXC-201 in relapsed/refractory AL Amyloidosis. Following management’s formal remarks, there will be a question-and-answer session. 

LOS ANGELES, July 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced that the 1st patient has been dosed at MSKCC in its U.S. NEXICART-2 trial with NXC-201, a sterically-optimized BCMA-targeted CAR-T cell therapy.

LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it will present and host institutional investor meetings at the Stifel 2024 Cell Therapy Forum.

European Orphan Drug Designation (“ODD”) qualifies NXC-201 for:

LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced Memorial Sloan Kettering Cancer Center as lead clinical site for its NXC-201 relapsed/refractory AL Amyloidosis multi-site clinical trial.

Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words

Immix Biopharma (NASDAQIMMX), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, has closed on its previously announced underwritten public offering. The offering consisted of 5,535,055 shares of IMMX common stock, with each share sold at $2.71 per share. Gross proceeds from the offering to ImmixBio are projected to be an estimated $15 million, before standard deductions and expenses. According to the announcement, ImmixBio plans to use funds from the offering for its NXC-201 clinical trials as well as working capital and general corporate purposes. Titan Partners Group, a division of American Capital Partners, acted as sole book-running manager for the offering.

LOS ANGELES, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced today the closing of its previously announced underwritten public offering of 5,535,055 shares of its common stock. Each share of common stock was sold at a price to the public of $2.71 per share. The gross proceeds to ImmixBio from this offering are expected to be approximately $15 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by ImmixBio. The Company intends to use the net proceeds from this offering for NXC-201 clinical trials, working capital and general corporate purposes.

European Orphan Drug Designation (“ODD”) qualifies NXC-201 for:

LOS ANGELES, CA, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that it has priced an underwritten public offering of 5,535,055 shares of its common stock at an offering price of $2.71 per share of common stock. ImmixBio has granted the underwriters a 30-day option to purchase up to 783,970 additional shares of its common stock sold in the offering on the same terms and conditions. The Company expects to close the offering on February 8, 2024, subject to the satisfaction of customary closing conditions.

LOS ANGELES, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (the “Company”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.  All of the shares of common stock in the underwritten public offering are to be sold by the Company. The Company also expects to grant the underwriters a 30-day option to purchase additional shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

LOS ANGELES, CA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced a statement on January 2024, FDA labeling change notifications for approved CAR-T products:

Dr. Sanchorawala co-authored landmark study of daratumumab (DARZALEX®) in AL Amyloidosis published in The New England Journal of Medicine, 2021 that led to it becoming a first-line standard of care